[go: up one dir, main page]

PT3529360T - Métodos de prevenção de eventos cardiovasculares através da redução da proteína pró-proteína convertase subtilisina quexina tipo 9 (pcsk9) - Google Patents

Métodos de prevenção de eventos cardiovasculares através da redução da proteína pró-proteína convertase subtilisina quexina tipo 9 (pcsk9)

Info

Publication number
PT3529360T
PT3529360T PT178009767T PT17800976T PT3529360T PT 3529360 T PT3529360 T PT 3529360T PT 178009767 T PT178009767 T PT 178009767T PT 17800976 T PT17800976 T PT 17800976T PT 3529360 T PT3529360 T PT 3529360T
Authority
PT
Portugal
Prior art keywords
pcsk9
reducing
methods
cardiovascular events
proprotein convertase
Prior art date
Application number
PT178009767T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60388127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3529360(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3529360T publication Critical patent/PT3529360T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/353Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
PT178009767T 2016-10-18 2017-10-18 Métodos de prevenção de eventos cardiovasculares através da redução da proteína pró-proteína convertase subtilisina quexina tipo 9 (pcsk9) PT3529360T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US201762550426P 2017-08-25 2017-08-25

Publications (1)

Publication Number Publication Date
PT3529360T true PT3529360T (pt) 2024-07-12

Family

ID=60388127

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178009767T PT3529360T (pt) 2016-10-18 2017-10-18 Métodos de prevenção de eventos cardiovasculares através da redução da proteína pró-proteína convertase subtilisina quexina tipo 9 (pcsk9)

Country Status (22)

Country Link
US (2) US20180104360A1 (pt)
EP (2) EP3529360B1 (pt)
JP (3) JP7181881B2 (pt)
KR (3) KR20250171391A (pt)
CN (4) CN119345221A (pt)
AU (2) AU2017346879B2 (pt)
BR (1) BR112019007843A2 (pt)
CA (1) CA3042423A1 (pt)
CL (1) CL2019001047A1 (pt)
DK (1) DK3529360T3 (pt)
ES (1) ES2982911T3 (pt)
FI (1) FI3529360T3 (pt)
HR (1) HRP20240930T1 (pt)
HU (1) HUE067712T2 (pt)
IL (1) IL266066A (pt)
LT (1) LT3529360T (pt)
MX (2) MX2019004573A (pt)
PL (1) PL3529360T3 (pt)
PT (1) PT3529360T (pt)
RS (1) RS65725B1 (pt)
SI (1) SI3529360T1 (pt)
WO (1) WO2018075658A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3336187A1 (en) 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9 irna compositions and methods of use thereof
EA201890571A1 (ru) 2015-08-25 2018-10-31 Элнилэм Фармасьютикалз, Инк. Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
MX2019004573A (es) 2016-10-18 2019-10-07 The Medicines Co Metodos para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3719128B1 (en) 2017-12-01 2025-01-15 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
KR20250107294A (ko) 2017-12-01 2025-07-11 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
JP7273417B2 (ja) 2017-12-01 2023-05-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド siRNA複合体及びその調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US12540323B2 (en) 2019-05-22 2026-02-03 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP4081642A1 (en) 2020-03-16 2022-11-02 Argonaute Rna Limited Antagonist of pcsk9
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ (シャーメン) バイオファーマ カンパニー,リミテッド 炭水化物-オリゴヌクレオチド複合体、薬物組成物および治療への応用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2584047B1 (en) * 2006-05-11 2014-11-19 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
EP3336187A1 (en) * 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9 irna compositions and methods of use thereof
EA201890571A1 (ru) * 2015-08-25 2018-10-31 Элнилэм Фармасьютикалз, Инк. Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
MX2019004573A (es) 2016-10-18 2019-10-07 The Medicines Co Metodos para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).

Also Published As

Publication number Publication date
JP2025016469A (ja) 2025-02-04
FI3529360T3 (fi) 2024-07-11
CN110088283A (zh) 2019-08-02
WO2018075658A1 (en) 2018-04-26
HUE067712T2 (hu) 2024-11-28
US20210093736A1 (en) 2021-04-01
HRP20240930T1 (hr) 2024-10-11
IL266066A (en) 2019-06-30
AU2023263519A1 (en) 2023-12-07
BR112019007843A2 (pt) 2019-10-01
DK3529360T3 (da) 2024-07-15
ES2982911T3 (es) 2024-10-18
KR20240067272A (ko) 2024-05-16
JP7181881B2 (ja) 2022-12-01
JP7566815B2 (ja) 2024-10-15
KR20190077411A (ko) 2019-07-03
AU2023263519B2 (en) 2026-02-12
CN119318663A (zh) 2025-01-17
EP3529360B1 (en) 2024-04-17
PL3529360T3 (pl) 2024-08-26
JP2022109948A (ja) 2022-07-28
CN119345221A (zh) 2025-01-24
KR20250171391A (ko) 2025-12-08
EP3529360A1 (en) 2019-08-28
EP4397311A3 (en) 2024-10-16
JP2019531357A (ja) 2019-10-31
CN119700800A (zh) 2025-03-28
LT3529360T (lt) 2024-07-25
SI3529360T1 (sl) 2024-08-30
AU2017346879B2 (en) 2023-11-30
MX2019004573A (es) 2019-10-07
CA3042423A1 (en) 2018-04-26
US20180104360A1 (en) 2018-04-19
EP4397311A2 (en) 2024-07-10
CL2019001047A1 (es) 2020-05-08
MX2024004495A (es) 2024-05-08
RS65725B1 (sr) 2024-08-30
AU2017346879A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
PT3529360T (pt) Métodos de prevenção de eventos cardiovasculares através da redução da proteína pró-proteína convertase subtilisina quexina tipo 9 (pcsk9)
IL310959A (en) Methods and preparations for treating a disorder related to the PCSK9 gene
IL257665A (en) Methods to lower the pcsk9 proprotein level
LT3256580T (lt) Cisteino proteazė
ZA201409210B (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
DK3274364T3 (da) Modificeret botulinumneurotoksin
IL253939B (en) cysteine protease
DK3212780T3 (da) Serinprotease
DK3212662T3 (da) Serinproteaser
DK3212781T3 (da) Serinproteaser
DK3679133T3 (da) Ydelsesforbedrede proteasevarianter
DK3487996T3 (da) Serinproteasevarianter og polynukleotider, der koder for samme
DK3356391T3 (da) Fremgangsmåde til oprensning af clostridial neurotoksin
DK3679131T3 (da) Ydelses-forbedrede proteasevarianter II
EP3337788A4 (en) PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
EP3182971A4 (en) Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
MX374276B (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
DK3085462T3 (da) Skivesigte til at adskille faste rester
DK3289069T3 (da) Mediumsammensætning til fremstilling af botulinumtoksin
DK3259364T3 (da) Fremgangsmåder til styring af proteasefremstilling
EP3562837A4 (en) MODIFIED LYSINE DECARBOXYLASE ENZYMES
BR112017020091A2 (pt) inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
DK3289070T3 (da) Mediumsammensætning til fremstilling af botulinumtoksin
FR3023480B1 (fr) Composition soft solid anhydre a base de particules encapsulant un agent benefique
GB201306127D0 (en) Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9)